Proceedings (Dec 2024)
Pre- and Post-partum Levels of Serum Visfatin in Pregnant Women with Gestational Diabetes Mellitus: A Correlation
Abstract
Introduction: Gestational diabetes mellitus is glucose intolerance diagnosed or detected for the first-time during pregnancy and has serious implications for fetal and maternal health if left untreated. Hyperglycemia during pregnancy is caused by the progressive increase in insulin resistance from mid to third trimester. Increased insulin resistance is a consequence of an increase in adipose tissue in mother and desensitizing effect to insulin by placental factors. Adipokine, visfatin, is multifunctional protein. Its levels are much higher in pregnant women. Aims and Objectives: To determine and compare levels of serum visfatin and insulin resistance before and after delivery in gestational diabetics. Place and Duration of Study: Lahore General Hospital Lahore/ PGMI, Lahore, during 2024. Materials and Methods: It was a Case control study. 21 Pregnant females at gestational age of 32-36 weeks were selected using non-probability purposive sampling as diagnosed cases of GDM (OGTT) matched with 21 control without GDM. Serum levels of Visfatin, Insulin, fasting blood Glucose and HOMA IR were determined. Data was analyzed by using SPSS version 20. Results were checked for normality. Paired t test was used to compare normally distributed data before and after delivery in the both groups. The Wilcoxon sign rank test was used to compare non normally distributed data before and after delivery. Spearman’s and Pearson correlation was used to correlate data. A p-value of <0.05 was considered significant. Results: A statistically significant difference (p-value=0.000) was determined between Serum visfatin and fasting insulin levels. A Statistically significant correlation (p-value=0.000) was found between Serum visfatin, insulin, FBG and HOMAIR before and after delivery. Conclusion: In GDM women comparison of visfatin before and after delivery showed a significant difference indicating that source of visfatin is likely the placenta, which due to prolonged hyperglycemia causes the release of visfatin. A significant correlation supporting the belief that enhanced insulin resistance during pregnancy leads to hyperglycemia causing an increased level of visfatin.
